Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tonglin Sun

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Frontiers in Immunology|November 7, 2022
Immunotherapeutic progress and application of bispecific antibody in cancerJingyue Kang, Tonglin Sun, Yan Zhang
Frontiers in Oncology|December 30, 2024
ILF2: a multifaceted regulator in malignant tumors and its prospects as a biomarker and therapeutic targetTonglin Sun, Xi Li, Yi Zhang, et al.
Medicine|April 7, 2025
Causal association of blood metabolites, immune cells, and lung cancer: A mediation Mendelian randomization studyTonglin Sun, Sheng Chen, Zhengyi Liu, et al.
Current Computer-Aided Drug Design|February 4, 2024
Astragaloside IV Overcomes Anlotinib Resistance in Non-small Cell Lung Cancer through miR-181a-3p/UPR-ERAD AxisLihuai Wang, Tonglin Sun, Xiao Yang, et al.
Anti-Cancer Agents in Medicinal Chemistry|April 8, 2024
Determination of Pralsetinib in Human Plasma and Cerebrospinal Fluid for Therapeutic Drug Monitoring by Ultra-performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS)Zichen Zhao, Qianlun Pu, Tonglin Sun, et al.
Critical Reviews in Oncology/Hematology|March 27, 2026
Pan-Cancer Perspectives on Post-Translational Modifications and Metastasis: Unraveling Complex Molecular MechanismsQilu Yan, Shuya Jiang, Wangzheqi Zhang, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Frontiers in Immunology|November 7, 2022
Immunotherapeutic progress and application of bispecific antibody in cancerJingyue Kang, Tonglin Sun, Yan Zhang
Frontiers in Oncology|December 30, 2024
ILF2: a multifaceted regulator in malignant tumors and its prospects as a biomarker and therapeutic targetTonglin Sun, Xi Li, Yi Zhang, et al.
Medicine|April 7, 2025
Causal association of blood metabolites, immune cells, and lung cancer: A mediation Mendelian randomization studyTonglin Sun, Sheng Chen, Zhengyi Liu, et al.
Current Computer-Aided Drug Design|February 4, 2024
Astragaloside IV Overcomes Anlotinib Resistance in Non-small Cell Lung Cancer through miR-181a-3p/UPR-ERAD AxisLihuai Wang, Tonglin Sun, Xiao Yang, et al.
Anti-Cancer Agents in Medicinal Chemistry|April 8, 2024
Determination of Pralsetinib in Human Plasma and Cerebrospinal Fluid for Therapeutic Drug Monitoring by Ultra-performance Liquid Chromatography-Tandem Mass Spectrometry (UPLC-MS/MS)Zichen Zhao, Qianlun Pu, Tonglin Sun, et al.
Critical Reviews in Oncology/Hematology|March 27, 2026
Pan-Cancer Perspectives on Post-Translational Modifications and Metastasis: Unraveling Complex Molecular MechanismsQilu Yan, Shuya Jiang, Wangzheqi Zhang, et al.
Pageof 1